November 5, 2020
Justin Lathia to present Division of Biology Seminar
Justin Lathia, associate professor in the Department of Cellular and Molecular Medicine at the Lerner Research Institute, a part of the Cleveland Clinic, will present "What Is Good for Adam May Not be Good for Eve: How Underlying Sex Difference in Glioblastoma May Provide New Insights" as part of the Division of Biology Seminar Series at 3:30 p.m. CST Monday, Nov. 9, via Zoom.
Glioblastoma, or GBM, is the most common primary malignant brain tumor and despite aggressive multi-modal therapies, including surgical resection and concomitant radiation and chemotherapy, is associated with a poor prognosis. The overall survival has not increased dramatically over the last 30 years and identifying targetable cellular and molecular mechanisms in GBM remains a priority. GBM has a sexual dimorphism in incidence and outcome, with males experiencing a higher incidence of GBM and a poorer prognosis. These sex differences are an emerging area of interest and studies have revealed sex-specific genetic aberrations and cellular programs that manifest in differences in imaging characteristics and therapeutic response. The seminar will include discussion of additional cellular and molecular insights using pre-clinical models in terms of immune response that underlie GBM progression. While GBM is being used as a paradigm for these assessments, these sex differences have implications for other advanced cancers and neurological disorders.
If you would like to visit with Lathia, please contact Nirupama Kotian at email@example.com.